-
Avalo Therapeutics NASDAQ:AVTX Avalo is a leading clinical-stage biopharmaceutical company that employs a precision medicine approach to discover, develop, and commercialize highly targeted therapeutics in areas of significant unmet clinical need.
Location: 540 Gaither Rd Ste 400, Maryland, 20850-6713, United States | Website: www.avalotx.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-66.17M
Cash
93.43M
Avg Qtr Burn
-8.022M
Short % of Float
8.96%
Insider Ownership
1.76%
Institutional Own.
39.21%
Qtr Updated
06/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
AVTX-803 (CERC-803) Details Leukocyte Adhesion Deficiency Type II | Phase 3 Data readout | |
AVTX-009 Details Hidradenitis suppurativa, Autoimmune disease | Phase 2 Data readout | |
Phase 2 Update | ||
Phase 2 Update | ||
AVTX-007 (CERC-007) Details Multiple myeloma, Adult Onset Still's Disease | Phase 1b Update | |
Quisovalimab/ AVTX-002 (CERC-002) Details Crohns disease | Phase 1b Update | |
AVTX-801 (CERC-801) Details Metabolic disorder, Rare genetic disease | Failed Discontinued | |
AVTX-802 (CERC-802) Details Metabolic disorder, Rare genetic disease | Failed Discontinued | |
AVTX-006 (CERC-006) Details Lymphatic malformations | Failed Discontinued |